Cytokinetics Inc [NASDAQ: CYTK] slipped around -2.2 points on Wednesday, while shares priced at $47.56 at the close of the session, down -4.42%.
Compared to the average trading volume of 1.85M shares, CYTK reached a trading volume of 7347199 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Cytokinetics Inc [CYTK]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYTK shares is $74.39 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYTK stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Cytokinetics Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 30, 2025. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on April 24, 2025, representing the official price target for Cytokinetics Inc stock. Previously, the target price had yet another raise to $86, while Citigroup analysts kept a Buy rating on CYTK stock.
How has CYTK stock performed recently?
Cytokinetics Inc [CYTK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.54. With this latest performance, CYTK shares gained by 22.11% in over the last four-week period, additionally plugging by 9.89% over the last 6 months – not to mention a rise of 1.11% in the past year of trading.
Cytokinetics Inc [CYTK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cytokinetics Inc [CYTK] shares currently have an operating margin of -637.96% and a Gross Margin at 89.06%. Cytokinetics Inc’s Net Margin is presently recorded at -707.17%.
Cytokinetics Inc (CYTK) Capital Structure & Debt Analysis
Cytokinetics Inc (CYTK) Efficiency & Liquidity Metrics
Cytokinetics Inc (CYTK) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Cytokinetics Inc. (CYTK) effectively leverages its workforce, generating an average of -$1217489.96 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.76% and a Quick Ratio of 6.76%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Cytokinetics Inc [CYTK]
With the latest financial reports released by the company, Cytokinetics Inc posted -1.36/share EPS, while the average EPS was predicted by analysts to be reported at -1.24/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.12. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CYTK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cytokinetics Inc go to 11.67%.
Insider trade positions for Cytokinetics Inc [CYTK]
There are presently around $117.95%, or 118.76%% of CYTK stock, in the hands of institutional investors. The top three institutional holders of CYTK stocks are: BLACKROCK INC. with ownership of 14.67 million shares, which is approximately 13.4317%. FMR LLC, holding 11.52 million shares of the stock with an approximate value of $$624.32 million in CYTK stocks shares; and FMR LLC, currently with $$619.69 million in CYTK stock with ownership which is approximately 10.4702%.
